Glizamide M 80-1000 Tablet contains Gliclazide 80 mg and Metformin 1000 mg, a potent dual antidiabetic formulation designed for patients with type 2 diabetes mellitus requiring intensified glycemic control. Gliclazide stimulates pancreatic insulin release, while Metformin reduces hepatic glucose output and improves peripheral glucose uptake.
Clinically, this combination is prescribed for patients inadequately controlled on single-agent therapy, especially where both insulin resistance and beta-cell dysfunction are present. The higher Gliclazide dose provides enhanced post-meal glucose regulation, while Metformin supports sustained basal glycemic control.
The tablet formulation ensures accurate dosing, stable bioavailability, and predictable therapeutic efficacy, making it suitable for endocrinology clinics, diabetes care centers, hospitals, and long-term outpatient therapy. Oral administration allows convenient once- or twice-daily dosing, improving patient compliance.
Glizamide M 80-1000 Tablet helps in lowering HbA1c levels, reducing glycemic variability, and minimizing the risk of diabetes-related complications. Its established clinical profile makes it a reliable combination therapy for comprehensive diabetes management under medical supervision.